Effect of Pirfenidone on NSCLC [A549 1.5 mg/ml Pirf 24hrs]

Investigating the effect of Pirfenidone on NSCLC cells Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated the single drug potency of Pirfenidone, an approved drug for the treatment of lung fibrosis which is known to inhibit TGFB1 mRNA. Human A549 and H1975 lung adenocarcinoma cell lines were stimulated for 6h and 25h with 0.75 mg/ml or 1.5 mg/ml Pirfenidone or the respective volume of PBS as vehicle control. Total RNA was extracted and subjected to transcriptome analysis by microarrays. stimulation of A549 cell line with 1.5 mg/ml Pirfenidone or equal volume of PBS and incubation 24h (N=4 each)

吡非尼酮（Pirfenidone）对非小细胞肺癌（NSCLC）细胞的作用研究
尽管免疫检查点疗法与靶向治疗为肺癌治疗带来了显著获益，但仍有部分患者无法适用此类治疗方案，或未获得持续稳定的疗效。鉴于肺癌的发生似乎由转化生长因子β（TGF-β）信号通路驱动，本研究探究了吡非尼酮的单药药效：吡非尼酮是一款已获批用于肺纤维化治疗的药物，已知其可抑制TGFB1 mRNA的表达。
本研究以人A549及H1975肺腺癌细胞系为模型，分别使用0.75 mg/ml、1.5 mg/ml的吡非尼酮，或等体积的磷酸盐缓冲液（PBS，溶剂对照）处理细胞，处理时长分别为6小时与25小时。提取总RNA后，通过基因芯片（microarrays）开展转录组分析。另有一组对照实验：以1.5 mg/ml吡非尼酮或等体积PBS处理A549细胞系并孵育24小时，每组生物学重复数为4